Nuvectis Pharma Investor Presentation Deck slide image

Nuvectis Pharma Investor Presentation Deck

Tumor Volume (mm³) Potent Antitumor Activity in ARID1 a/ARID1b Mutated Endometrial Carcinoma Xenografts ARID1a is the most frequently mutated SWI/SNF subunit with an estimated prevalence of 35% in endometrial carcinomas. Inactivation of ARID1b is highly prevalent in undifferentiated and dedifferentiated endometrial cancers (approx. 36%), often concurrent with ARID1a, and is associated with an aggressive phenotype. T 800 600 400 200 Day 0 NXP800 demonstrated robust antitumor activity in ARID1a and ARID1b mutated xenografts of endometrial carcinoma, at a well- tolerated dose, including in models of poorly differentiated tumors, supporting the clinical development of NXP800 in endometrial cancer. RL95-2 (ARID1a/ARID1b concurrent mutation) Vehicle NXP800 (35 mg/kg) Day 3 Day 5 Day 7 Day 12 Day 10 Day 14 NuvectisPharma, Inc. Day 17 Day 19 Day 21 Day 24 Day 26 Day 28 Day 32 Tumor Volume (mm³) 250 200 150 100 50 0 Day 0 KLE (ARID1b mutation/poorly differentiated) Day 3 Vehicle NXP800 (35 mg/kg) Day 5 Day 7 Day 12 Day 10 Day 14 Day Day 21 Day 19 Day 26 Day 24 Day 28 Day 32 Tumor Volume (mm³) 500 400 300 200 100 Vehicle NXP800 (35 mg/kg) Day 0 Day 2 Day 5 Day 7 (ARID1a mutation) SNG-M Day 9 Day 13 Day 16 Day 21 Day 19 Day 23 Day 26 Day 28 Day 30 11
View entire presentation